Saturday 17 October 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.3%, EPS grew 40.7% and free cash flow grew 33.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.03
0.04
−3.74%
Follow LSTA
Lisata Therapeutics, Inc. (LSTA) P/E ratio
Lisata Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.4× (July 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2016 | 0.0× | — |
| Dec 2015 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.4×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GDTC CytoMed Therapeutics Limited compare | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| BIVI BioVie Inc. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| TOVX Theriva Biologics, Inc. compare | 0.1× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)